{"type":"trials","record":{"id":41618,"source_id":"clinicaltrials-gov","external_id":"NCT04796545","title":"Post-market Clinical Investigation of the SING IMT System, Model NG SI IMT 3X in Patients With End-stage Age-related Macular Degeneration","brief_summary":"The objective of this study is to demonstrate the safety and effectiveness of the SING IMT (Smaller Incision New Generation Implantable Miniature Telescope) 3X implant in improving vision in patients with central vision impairment associated with end-stage Age-related Macular Degeneration (AMD). Eligible patients will be implanted with the SING IMT device and will be followed-up for a period of 12-months with post-operative ophthalmic exams and low-vision rehabilitation sessions.","overall_status":"Recruiting","phases":[],"study_type":"INTERVENTIONAL","sponsor":"VisionCare, Inc.","enrollment":76,"countries":["Belgium","France","Germany","Ireland","Italy","Spain","United Kingdom"],"start_date":"2022-09-13","completion_date":"2028-12-01","last_update_date":"2026-02-10","source_url":"https://clinicaltrials.gov/study/NCT04796545","editorial_summary":"A registered study indexed because it matched monitored longevity research terms. Registry status: Recruiting. Registration does not establish safety or effectiveness.","first_seen_at":"2026-09-25T01:25:30.378222+00:00","last_seen_at":"2026-09-25T06:20:47.789+00:00","metadata":{"sex":"ALL","acronym":null,"age_range":"55 Years","comparator":null,"organization":"VisionCare, Inc.","interventions":["SING IMT(TM) System, model NG SI IMT 3X"],"registry_source":"ClinicalTrials.gov","outcome_measures":["Safety of the SING IMT System, model NG SI IMT 3X, including its delivery system — 12 months","Incision size needed for device implantation — 12 moths","Surgical complications — 12 moths","Improvement in near and distance best corrected visual acuity (BCVA) in implanted eyes. — 12 months","Usability of SING IMT System, including delivery system — 12 months"],"design_description":"NA · SINGLE GROUP · OTHER · NONE","source_has_results":false},"controlled_terms":["AMD","Age-Related Macular Degeneration","SING IMT(TM) System, model NG SI IMT 3X"],"relevance_confidence":100,"source_quality_score":100,"freshness_score":85,"publication_state":"published","match_explanation":"Title contains controlled term: age-related macular degeneration.","quality_checked_at":"2026-09-25T06:20:59.355028+00:00","duplicate_cluster_key":"id:nct04796545","duplicate_of_id":null,"evidence_snapshot":{"status":"structured","version":1,"duration":"2022-09-13 to 2028-12-01","comparator":null,"confidence":"structured-source","population":"ALL · 55 Years","provenance":{"duration":"start_date and completion_date","comparator":"registry arm fields","population":"registry eligibility fields","intervention":"registry intervention fields","participants":"enrollment","study_design":"study_type and registry design fields","evidence_stage":"phases","reported_outcome":"not available","outcomes_measured":"registry outcome-measure fields"},"generated_at":"2026-09-25T06:20:47.842Z","intervention":["SING IMT(TM) System, model NG SI IMT 3X"],"participants":76,"study_design":"NA · SINGLE GROUP · OTHER · NONE","subject_scope":"Human clinical study registration","evidence_stage":"Phase not reported","safety_context":"Eligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians.","source_support":"Structured registry protocol metadata; no finding-level conclusion is generated.","main_limitation":"This is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.","reported_outcome":null,"outcomes_measured":["Safety of the SING IMT System, model NG SI IMT 3X, including its delivery system — 12 months","Incision size needed for device implantation — 12 moths","Surgical complications — 12 moths","Improvement in near and distance best corrected visual acuity (BCVA) in implanted eyes. — 12 months","Usability of SING IMT System, including delivery system — 12 months"],"regulatory_context":"Trial registration is not regulatory approval and does not establish that an intervention is available."},"clinical_trial_topics":[{"topic_slug":"vision-aging","is_published":true,"match_reasons":["Title contains controlled term: age-related macular degeneration.","Abstract contains controlled term: age-related macular degeneration.","Source terminology contains: age-related macular degeneration.","Title supplies longevity context: age-related.","Study type is explicitly identified as INTERVENTIONAL."],"matched_fields":["title","abstract","controlled terminology","title context","study type"],"relevance_score":100,"intelligence_topics":{"name":"Vision ageing","slug":"vision-aging"}}],"content_sources":{"name":"ClinicalTrials.gov","homepage_url":"https://clinicaltrials.gov/"}},"canonical_url":"https://www.immortal.life/trials/41618","automation_disclosure":"Generated automatically from cited source metadata. No scientist, clinician, researcher, editor, or human reviewer evaluates this publication before release."}